# First in Men Study: BIOMAG-I

Study · id `cardio:ct-nct04157153` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04157153](<https://clinicaltrials.gov/study/NCT04157153>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04157153

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A trial with no phase registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 116 participants.

## Technical summary

Registry record NCT04157153. Allocation not applicable; no masking; primary purpose treatment. Start 2020-04-27 (actual); primary completion 2022-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Not applicable
- Enrolled: 116 participants (enrolled count; ClinicalTrials.gov record NCT04157153, source copy `cardio:ctgov-nct04157153-2022-07-22`, retrieved 2026-10-26)
- Started: 2020-04-27 (actual) (ClinicalTrials.gov record NCT04157153, source copy `cardio:ctgov-nct04157153-2022-07-22`, retrieved 2026-10-26)
- Primary completion: 2022-08 (anticipated) (ClinicalTrials.gov record NCT04157153, source copy `cardio:ctgov-nct04157153-2022-07-22`, retrieved 2026-10-26)
- Completion: 2027-02 (anticipated) (ClinicalTrials.gov record NCT04157153, source copy `cardio:ctgov-nct04157153-2022-07-22`, retrieved 2026-10-26)
- Countries: Austria; Belgium; Germany; Netherlands; Poland; Spain; Sweden; Switzerland (ClinicalTrials.gov record NCT04157153, source copy `cardio:ctgov-nct04157153-2022-07-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04157153-2022-07-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: First in Men Study: BIOMAG-I
- Condition: Coronary Artery Disease
- Intervention (Device): Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold
- Lead sponsor: Biotronik AG
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Biotronik AG (`cardio:org-biotronik-ag`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: The Impact of Underlying Plaque Characteristics Following the Third-Generation Resorbable Magnesium Scaffold Implantation: An Intravascular OCT Assessment up to 12-Months (`cardio:pubmed-40091374`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e0b393a8779e2b6d21279111441b0943640a74b1f719b213dd831626f9a94e2c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
